Poster Presentation 13th Australian Peptide Conference 2019

Precisely controlled intracellular trafficking and enhanced gene silencing of nucleic acid-peptide conjugates. (#143)

Masayuki Fujii 1
  1. Kinkai University, Iizuka, FUK, Japan

Recently we reported that intracellular trafficking of oligonucleotides could be controlled by conjugation with nuclear export signal (NES) and nuclear localization signal (NLS) peptides and that siRNA-NES conjugates showed drastically enhanced silencing of BCR/ABL chimeric gene in human chronic myelogenous leukemia cell line K562 [1, 2, 3].

Herein we described the synthesis of siRNA-NES (nuclear export signal) peptide conjugates by solid phase fragment coupling (SPFC) and application of them to silencing of bcr/abl chimeric gene in human leukemia cell line K562.

Syntheses of siRNA-NES conjugates were achieved by SPFC as previously described .[1]

As a result, two types of siRNA-NES conjugates C1 and C2 were prepared in which 5’-end of sense strand was covalently linked to N-terminus of the NES peptides derived from TFIIIA for C1 and HIV-1 rev for C2, respectively. Silencing effects of C1 and C2 against bcr/abl mRNA in human leukemia cell line K562 were evaluated by quantitative PCR. The expression of bcr/abl gene was suppressed to 30.2 % at 200nM and 36.3 % at 50 nM by native siRNA. Significant enhancement of silencing efficiency was observed with C1 and C2. siRNA-TFIIIA NES (C1) suppressed the expression of bcr/abl gene to 8.3% at 200 nM and 11.6 % at 50nM and siRNA-HIV-1rev NES (C2) suppressed to 4.0 % at 200 nM and 6.3 % at 50nM. Previously, we reported that DNA-HIV-1 rev NES peptide conjugate was localized in cytoplasm of Jurkat cell. [2] The large enhancement of the silencing efficiency of siRNA-NES conjugates could be reasonably ascribed to the localization of siRNA-NES conjugates in cytoplasm. It can be also pointed out that modification of 5’-endo of sense strand reduced off-target effect by minimizing the extent of the sense strand incorporation into RISC. [3]

The author is grateful for financial support by JSPS KAKEN Grant Number 22550159, MAFF/AFFRCS International Joint Project 2017-03, JMRF-RFBR Japan-Russia Joint Research Project 2018-P2 and Kindai Research Grant KD201704.

  1. 1. M. Fujii, et al., Org. Lett., 2003, 5, 2623-2626. 2. M. Fujii, et al., Org. Biomol. Chem., 2005, 3, 3257-3259. 3. M. Fujii, et al., Nucleic Acid Therapeutics, 2017, 27(3), 168-175.